The life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, has recently announced that it has signed an agreement with the Instituto de Química Orgánica General ("IQOG") of the Spanish National Research Council based in Madrid. IQCG will carry out work on Optibiotix’s oiligosaccharride programme, with a view to human studies commencing in 2016. This propels OptiBiotix’s earliest stage programme a step further towards commerciali
